Wednesday, 6 June 2018

Rising Healthcare Demand Enables 100+ Year Dividend-Paying Pharma Giant to Enter Best Dividend Stocks List


Trouble viewing this?
View Email as Webpage

Rising Healthcare Demand Enables 100+ Year Dividend-Paying Pharma Giant to Enter Best Dividend Stocks List

Dividend.com has added an international pharmaceutical giant to the Best Dividend Stocks List and removed an industrial basic materials company from the list.

One of the biggest trends for the long haul happens to be rising healthcare demand. On the one hand, our rapidly aging population is requiring more therapies to keep us going for longer. On the other, rising incomes in emerging markets and other nations are allowing people to tap into new healthcare solutions for the first time. The combination of these two pieces is creating one heck of a bullish tailwind for the healthcare sector.

This is all wonderful news for our latest Best Dividend Stocks List pick.

As one of the largest pharmaceutical firms on the planet, our new pick has been designing new drugs and therapies for decades. This includes several cash-minting blockbuster drugs throughout its history. Those drugs have continued to power the firm's dividend growth and robust buyback program. It managed to hand out more than $1.5 billion to shareholders during the first quarter alone. Meanwhile, a very full-bodied pipeline program – with exposure to new biotech and cancer-fighting medicines – should continue to provide our pick with plenty of cash flows and earnings power into the future. The ability to buy promising rivals – thanks to its massive size – doesn't hurt either.

In the end, the prognosis for our new pick is certainly healthy. Its current and future portfolio will continue to throw off plenty of cash flows and help pad its already juicy dividend. For dividend investors, our new pick offers plenty of opportunity.

Five reasons why you should own this stock:

  • One of the world's largest pharmaceuticals with clinical operations conducted in more than 55 countries.
  • Features a robust portfolio of drugs – currently numbering over 30 as well as a few blockbuster franchises.
  • Recorded revenues of more than $20 billion last year – a 7% increase over the previous year's number.
  • Recently increased quarterly dividend by more than 8% and, thanks to the new tax law, the company is likely to repatriate close to $9 billion in overseas earnings.
  • Healthy payout ratio of 43% and increasing yield of 2.65%.
Stock Symbol  Unlock   Company Name  Unlock
DARS Rating 5.0   Current Yield 2.64%
Ex-Div Date  Unlock   Pay Date  Unlock
All data in the table above updated as of 06/06/2018.

UPGRADE TO UNLOCK THIS STOCK!
 
MORE ABOUT THIS STOCK

Trailing 5-Year Dividend Payout History

  • Annualized Growth Over The Last 5 Years: 1.2%.

As a dividend investor, you need access to the best and safest stocks on the market. Dividend.com’s DARS ratings have been providing you with reliable and profitable stock analysis since 2008, and this addition is no exception.

UPGRADE TO UNLOCK THIS STOCK!

Our mailing address is:
Dividend.com P.O. Box 822 New York, NY 10108 USA

Update Subscription Options | Unsubscribe From This List | Forward to a Friend

©2018 Dividend.com. All rights reserved. You are receiving this mailing because you opted-in at our website, Dividend.com, which is in full compliance of the CAN-SPAM Act of 2008.

Mitre Media

No comments:

Post a Comment